Key terms

About MRSN

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest MRSN news

Mar 19 4:50am ET Mersana Therapeutics upgraded to Neutral from Underweight at JPMorgan by TipRanks Mar 12 8:37am ET Mersana Therapeutics (MRSN) Gets a Buy from Truist Financial by TipRanks Mar 01 1:07am ET Buy Rating Affirmed for Mersana Therapeutics Amid Promising ADC Developments and Upcoming Milestones by TipRanks Feb 29 7:48am ET Wedbush bullish on Mersana Therapeutics, upgrades to Outperform by TipRanks Feb 29 7:19am ET Truist Financial upgrades Mersana Therapeutics (MRSN) to a Buy by TipRanks Feb 29 7:09am ET Mersana Therapeutics upgraded to Buy from Hold at Truist by TipRanks Feb 29 6:05am ET Mersana Therapeutics upgraded to Outperform from Neutral at Wedbush by TipRanks Feb 29 5:14am ET Guggenheim upgrades Mersana Therapeutics on XMT-1660 potential by TipRanks Feb 29 1:03am ET Bad News for Mersana Therapeutics Stock: This New Risk Has Been Added by TipRanks Feb 28 7:59pm ET Mersana Therapeutics upgraded to Buy from Neutral at Guggenheim by TipRanks Feb 28 3:55pm ET Mersana Therapeutics upgraded to Buy from Neutral at BTIG by TipRanks Feb 28 12:55pm ET TD Cowen Sticks to Its Buy Rating for Mersana Therapeutics (MRSN) by TipRanks Feb 28 7:22am ET Mersana Therapeutics Shares Corporate Presentation Update by TipRanks Feb 28 7:11am ET Mersana Therapeutics reports Q4 EPS (16c), consensus (16c) by TipRanks Jan 12 11:36am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Jan 11 11:25am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Jan 11 11:25am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Jan 09 1:07am ET Mersana Therapeutics: A Cautious Hold Amid Clinical and Strategic Uncertainties by TipRanks Jan 07 5:31am ET Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), GeneDx Holdings (WGS) and Mersana Therapeutics (MRSN) by TipRanks Jan 05 8:17am ET Mersana Therapeutics announces business updates, expected 2024 milestones by TipRanks Jan 02 9:34am ET BTIG Sticks to Their Hold Rating for Mersana Therapeutics (MRSN) by TipRanks Dec 31 5:21am ET BTIG Remains a Hold on Mersana Therapeutics (MRSN) by TipRanks

No recent press releases are available for MRSN

MRSN Financials

1-year income & revenue

Key terms

MRSN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

MRSN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

People walk past the New York Stock Exchange (NYSE) on March 28, 2024 in New York City.
NDZ/STAR MAX/IPx/AP
What stalled this year’s seemingly infallible stock market rally
A working oil pumpjack is pictured in Taft, Kern County, California on September 21, 2023.
Frederic J. Brown/AFP/Getty Images
Oil prices get short-lived boost from attack on Iran
NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue
Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days